Other mutant selective drugs like STX four seventy-eight are close behind it in earlier phase trials.

[outro jingle] So ESR1 codes for the estrogen receptor itself, and we know that mutations in the part of the estrogen receptor that bind to a lot of compounds like estrogen itself, like tamoxifen, that binding can be altered when it's mutated.

I said that with PIK3CA, it's about forty percent of women with breast cancer.

ESR1, the true number I think is still a little controversial.

It's anywhere from ten percent to maybe twenty percent in my estimation.

I say this because some of the trials when they've done retesting in the blood, they've come up with larger numbers depending on what the denominator is.

This is getting into the weeds of the epidemiology, but what the denominator is, numbers anywhere from ten percent to as high as in the forty percent range.

Could we shift a little bit and talk about ctDNA and the ctDNA testing?

So how does one get to speak on behalf of the patients, I guess, in this case? You register

on the website.

And generally, there's many patients as individuals will speak.

Sometimes caretakers speak.

Sometimes patient advocacy group directors speak.

Sometimes oncologists speak.

It's a mixture of in-person and virtual.

And so was that something that was discussed as part of the justification for PFS2? Yeah.